1. Metabolic agents in the management of diabetic coronary patients: a new era.
- Author
-
Celik T, Kursaklioglu H, Iyisoy A, and Jata B
- Subjects
- Carnitine therapeutic use, Coronary Disease complications, Coronary Disease physiopathology, Diabetes Mellitus metabolism, Diabetes Mellitus physiopathology, Dichloroacetic Acid therapeutic use, Enzyme Inhibitors therapeutic use, Epoxy Compounds therapeutic use, Humans, Perhexiline therapeutic use, Trimetazidine therapeutic use, Vasodilator Agents therapeutic use, Vitamin B Complex therapeutic use, Coronary Disease drug therapy, Diabetes Mellitus drug therapy, Diabetic Angiopathies complications
- Abstract
Modulation of myocardial free fatty acid metabolism is the key target for metabolic interventions in patients with coronary artery disease (CAD) with diabetes mellitus (DM). Because of its beneficial effects on heart metabolism at rest and on myocardial ischemia and left ventricular function, trimetazidine should be always combined with classical anti-ischemic treatment in patients with DM with CAD. We believe that, the new metabolic agents including L-carnitine, dichloroacetate, perhexiline and etomoxir will be added into our arsenal for the battle against CAD especially in patients with DM in the near future.
- Published
- 2008
- Full Text
- View/download PDF